407 related articles for article (PubMed ID: 17374533)
1. Increased sensitivity of adolescent spontaneously hypertensive rats, an animal model of attention deficit hyperactivity disorder, to the locomotor stimulation induced by the cannabinoid receptor agonist WIN 55,212-2.
Pandolfo P; Pamplona FA; Prediger RD; Takahashi RN
Eur J Pharmacol; 2007 Jun; 563(1-3):141-8. PubMed ID: 17374533
[TBL] [Abstract][Full Text] [Related]
2. Cannabinoid-induced conditioned place preference in the spontaneously hypertensive rat-an animal model of attention deficit hyperactivity disorder.
Pandolfo P; Vendruscolo LF; Sordi R; Takahashi RN
Psychopharmacology (Berl); 2009 Aug; 205(2):319-26. PubMed ID: 19407992
[TBL] [Abstract][Full Text] [Related]
3. Caffeine and cannabinoid receptors modulate impulsive behavior in an animal model of attentional deficit and hyperactivity disorder.
Leffa DT; Ferreira SG; Machado NJ; Souza CM; Rosa FD; de Carvalho C; Kincheski GC; Takahashi RN; Porciúncula LO; Souza DO; Cunha RA; Pandolfo P
Eur J Neurosci; 2019 Jun; 49(12):1673-1683. PubMed ID: 30667546
[TBL] [Abstract][Full Text] [Related]
4. Cannabinoid system of the lateral septum in the modulation of anxiety-like behaviors in rats.
Hajizadeh Moghaddam A; Bigdellu R; Fatemi Tabatabaei SR; Roohbakhsh A
Arch Iran Med; 2013 Dec; 16(12):711-6. PubMed ID: 24329144
[TBL] [Abstract][Full Text] [Related]
5. Behavioural disturbances and altered Fos protein expression in adult rats after chronic pubertal cannabinoid treatment.
Wegener N; Koch M
Brain Res; 2009 Feb; 1253():81-91. PubMed ID: 19094973
[TBL] [Abstract][Full Text] [Related]
6. Cannabinoid type 1 receptor ligands WIN 55,212-2 and AM 251 alter anxiety-like behaviors of marmoset monkeys in an open-field test.
Cagni P; Barros M
Behav Brain Res; 2013 Mar; 240():91-4. PubMed ID: 23183218
[TBL] [Abstract][Full Text] [Related]
7. Effects of cannabinoid and vanilloid drugs on positive and negative-like symptoms on an animal model of schizophrenia: the SHR strain.
Almeida V; Peres FF; Levin R; Suiama MA; Calzavara MB; Zuardi AW; Hallak JE; Crippa JA; Abílio VC
Schizophr Res; 2014 Mar; 153(1-3):150-9. PubMed ID: 24556469
[TBL] [Abstract][Full Text] [Related]
8. Influence of intracerebroventricular or intraperitoneal administration of cannabinoid receptor agonist (WIN 55,212-2) and inverse agonist (AM 251) on the regulation of food intake and hypothalamic serotonin levels.
Merroun I; Errami M; Hoddah H; Urbano G; Porres JM; Aranda P; Llopis J; López-Jurado M
Br J Nutr; 2009 May; 101(10):1569-78. PubMed ID: 19245736
[TBL] [Abstract][Full Text] [Related]
9. Cardiovascular effects of cannabinoids in conscious spontaneously hypertensive rats.
Wheal AJ; Bennett T; Randall MD; Gardiner SM
Br J Pharmacol; 2007 Nov; 152(5):717-24. PubMed ID: 17700721
[TBL] [Abstract][Full Text] [Related]
10. Effects of acute systemic and intra-cerebral stimulation of cannabinoid receptors on sensorimotor gating, locomotion and spatial memory in rats.
Wegener N; Kuhnert S; Thüns A; Roese R; Koch M
Psychopharmacology (Berl); 2008 Jun; 198(3):375-85. PubMed ID: 18446326
[TBL] [Abstract][Full Text] [Related]
11. The spontaneously hypertensive rat/Izm (SHR/Izm) shows attention deficit/hyperactivity disorder-like behaviors but without impulsive behavior: therapeutic implications of low-dose methylphenidate.
Kishikawa Y; Kawahara Y; Yamada M; Kaneko F; Kawahara H; Nishi A
Behav Brain Res; 2014 Nov; 274():235-42. PubMed ID: 25151620
[TBL] [Abstract][Full Text] [Related]
12. Dysregulation of the endogenous cannabinoid system in adult rats prenatally treated with the cannabinoid agonist WIN 55,212-2.
Castelli MP; Paola Piras A; D'Agostino A; Pibiri F; Perra S; Gessa GL; Maccarrone M; Pistis M
Eur J Pharmacol; 2007 Nov; 573(1-3):11-9. PubMed ID: 17644084
[TBL] [Abstract][Full Text] [Related]
13. Behavioral effects in adult rats of chronic prepubertal treatment with the cannabinoid receptor agonist WIN 55,212-2.
Schneider M; Drews E; Koch M
Behav Pharmacol; 2005 Sep; 16(5-6):447-54. PubMed ID: 16148450
[TBL] [Abstract][Full Text] [Related]
14. Intrinsic effects of AM4113, a putative neutral CB1 receptor selective antagonist, on open-field behaviors in rats.
Järbe TU; LeMay BJ; Olszewska T; Vemuri VK; Wood JT; Makriyannis A
Pharmacol Biochem Behav; 2008 Nov; 91(1):84-90. PubMed ID: 18640150
[TBL] [Abstract][Full Text] [Related]
15. Differences in the relative potency of SR 141716A and AM 251 as antagonists of various in vivo effects of cannabinoid agonists in C57BL/6J mice.
McMahon LR; Koek W
Eur J Pharmacol; 2007 Aug; 569(1-2):70-6. PubMed ID: 17553486
[TBL] [Abstract][Full Text] [Related]
16. Effects of SR141716 and WIN 55,212-2 on tolerance to ethanol in rats using the acute and rapid procedures.
Lemos JI; Takahashi RN; Morato GS
Psychopharmacology (Berl); 2007 Oct; 194(2):139-49. PubMed ID: 17546513
[TBL] [Abstract][Full Text] [Related]
17. Effects of the cannabinoid receptor agonist WIN 55,212-2 on operant behavior and locomotor activity in rats.
Drews E; Schneider M; Koch M
Pharmacol Biochem Behav; 2005 Jan; 80(1):145-50. PubMed ID: 15652390
[TBL] [Abstract][Full Text] [Related]
18. Methamphetamine neurotoxicity increases brain expression and alters behavioral functions of CB₁ cannabinoid receptors.
Bortolato M; Frau R; Bini V; Luesu W; Loriga R; Collu M; Gessa GL; Ennas MG; Castelli MP
J Psychiatr Res; 2010 Oct; 44(14):944-55. PubMed ID: 20378129
[TBL] [Abstract][Full Text] [Related]
19. Antinociceptive effect of the cannabinoid agonist, WIN 55,212-2, in the orofacial and temporomandibular formalin tests.
Burgos E; Pascual D; Martín MI; Goicoechea C
Eur J Pain; 2010 Jan; 14(1):40-8. PubMed ID: 19318283
[TBL] [Abstract][Full Text] [Related]
20. Intravenous self-administration of the cannabinoid CB1 receptor agonist WIN 55,212-2 in rats.
Fattore L; Cossu G; Martellotta CM; Fratta W
Psychopharmacology (Berl); 2001 Aug; 156(4):410-6. PubMed ID: 11498718
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
